LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

This is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

Trial Details

NCT ID
NCT07362186
Phase
PHASE3
Sponsor
LaNova Medicines Limited
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • LM-108 in combination with Toripalimab
  • Paclitaxel injection intravenous infusion
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Individuals who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
  • Age 18 years or older, male or female.
  • Weight ≥ 40 kg or Body Mass Index (BMI)≥ 18.5 kg/m²
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →